Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition is launching unbuzzd™, an alcohol detoxification and anti-hangover beverage, in Puerto Rico through FUSION Distribution Group.
unbuzzd™, scientifically validated through a double-blind placebo-controlled crossover study, is designed to accelerate alcohol metabolism and reduce hangover symptoms. The product will be available in single-serve powder stick packs through FUSION's extensive retail network, including major retailers like Walmart, Walgreens, Costco, Sam's, and various supermarket chains.
FUSION Distribution Group, which already distributes notable brands like CELSIUS Energy Drinks and Kin Whiskey, will initially launch unbuzzd™ in Puerto Rico before expanding across the Caribbean region. The product will be available in grocery stores, pharmacies, convenience stores, hotels, bars, and restaurants.
Quantum BioPharma (NASDAQ: QNTM) ha annunciato che il suo licenziatario Celly Nutrition sta lanciando unbuzzd™, una bevanda per la disintossicazione dall'alcol e per combattere i postumi di una sbornia, a Porto Rico attraverso FUSION Distribution Group.
unbuzzd™, scientificamente convalidato tramite uno studio crossover controllato con placebo in doppio cieco, è progettato per accelerare il metabolismo dell'alcol e ridurre i sintomi della sbornia. Il prodotto sarà disponibile in bustine monodose in polvere attraverso la vasta rete di vendita al dettaglio di FUSION, che include grandi rivenditori come Walmart, Walgreens, Costco, Sam's e diverse catene di supermercati.
FUSION Distribution Group, che già distribuisce marchi noti come CELSIUS Energy Drinks e Kin Whiskey, lancerà inizialmente unbuzzd™ a Porto Rico prima di espandersi nella regione dei Caraibi. Il prodotto sarà disponibile in supermercati, farmacie, negozi di alimentari, hotel, bar e ristoranti.
Quantum BioPharma (NASDAQ: QNTM) anunció que su licenciatario Celly Nutrition está lanzando unbuzzd™, una bebida para la desintoxicación de alcohol y para combatir la resaca, en Puerto Rico a través de FUSION Distribution Group.
unbuzzd™, validado científicamente a través de un estudio cruzado controlado con placebo, está diseñado para acelerar el metabolismo del alcohol y reducir los síntomas de la resaca. El producto estará disponible en paquetes de polvo de una sola porción a través de la extensa red de venta al por menor de FUSION, que incluye grandes minoristas como Walmart, Walgreens, Costco, Sam's y diversas cadenas de supermercados.
FUSION Distribution Group, que ya distribuye marcas notables como CELSIUS Energy Drinks y Kin Whiskey, lanzará inicialmente unbuzzd™ en Puerto Rico antes de expandirse por la región del Caribe. El producto estará disponible en supermercados, farmacias, tiendas de conveniencia, hoteles, bares y restaurantes.
Quantum BioPharma (NASDAQ: QNTM)은 자사의 라이센스 회사인 Celly Nutrition이 푸에르토리코에서 FUSION Distribution Group을 통해 알코올 해독 및 숙취 해소 음료인 unbuzzd™를 출시한다고 발표했습니다.
unbuzzd™는 이중 맹검 위약 대조 연구를 통해 과학적으로 검증되었으며, 알코올 대사를 가속화하고 숙취 증상을 줄이도록 설계되었습니다. 이 제품은 FUSION의 광범위한 소매 네트워크를 통해 월마트, 월그린스, 코스트코, 샘스 및 다양한 슈퍼마켓 체인과 같은 주요 소매업체에서 단일 서빙 파우더 스틱 팩으로 제공될 것입니다.
CELSIUS Energy Drinks 및 Kin Whiskey와 같은 저명한 브랜드를 이미 유통하고 있는 FUSION Distribution Group은 처음에 푸에르토리코에서 unbuzzd™를 출시한 후 카리브해 지역으로 확장할 예정입니다. 이 제품은 식료품점, 약국, 편의점, 호텔, 바 및 레스토랑에서 제공될 것입니다.
Quantum BioPharma (NASDAQ: QNTM) a annoncé que son licencié Celly Nutrition lançait unbuzzd™, une boisson pour la détoxification de l'alcool et pour lutter contre la gueule de bois, à Porto Rico via FUSION Distribution Group.
unbuzzd™, validé scientifiquement par une étude croisée contrôlée par placebo en double aveugle, est conçu pour accélérer le métabolisme de l'alcool et réduire les symptômes de la gueule de bois. Le produit sera disponible en sachets de poudre à dose unique à travers le vaste réseau de distribution de FUSION, incluant des détaillants majeurs comme Walmart, Walgreens, Costco, Sam's et diverses chaînes de supermarchés.
FUSION Distribution Group, qui distribue déjà des marques notables comme CELSIUS Energy Drinks et Kin Whiskey, lancera d'abord unbuzzd™ à Porto Rico avant de s'étendre dans la région des Caraïbes. Le produit sera disponible dans les épiceries, les pharmacies, les magasins de proximité, les hôtels, les bars et les restaurants.
Quantum BioPharma (NASDAQ: QNTM) gab bekannt, dass sein Lizenznehmer Celly Nutrition unbuzzd™, ein Getränk zur Alkoholentgiftung und zur Bekämpfung von Kater, in Puerto Rico über FUSION Distribution Group auf den Markt bringt.
unbuzzd™, wissenschaftlich validiert durch eine doppelblinde Placebo-kontrollierte Crossover-Studie, wurde entwickelt, um den Alkoholstoffwechsel zu beschleunigen und die Symptome eines Katers zu reduzieren. Das Produkt wird in Portionsbeuteln als Pulver über das umfangreiche Einzelhandelsnetz von FUSION erhältlich sein, das große Einzelhändler wie Walmart, Walgreens, Costco, Sam's und verschiedene Supermarktketten umfasst.
FUSION Distribution Group, die bereits namhafte Marken wie CELSIUS Energy Drinks und Kin Whiskey vertreibt, wird unbuzzd™ zunächst in Puerto Rico einführen, bevor es in der Karibikregion expandiert. Das Produkt wird in Lebensmittelgeschäften, Apotheken, Convenience-Stores, Hotels, Bars und Restaurants erhältlich sein.
- Product expansion into new geographic market through established distributor
- Access to major retail chains through FUSION's distribution network
- Product validated by scientific study showing effectiveness
- Revenue impact and commercial terms of distribution agreement not disclosed
Insights
Quantum BioPharma's announcement showcases incremental market expansion through its licensee Celly Nutrition, but with immediate financial significance. The launch of unbuzzd in Puerto Rico through FUSION Distribution represents a strategic geographic expansion that provides access to major retailers including Walmart, Walgreens, and Costco.
What's notable here is Quantum's licensing business model - they're generating value through intellectual property rather than direct operations, which typically offers higher margins but lower absolute revenue. The Puerto Rico launch appears to be a stepping stone toward broader Caribbean distribution as explicitly mentioned by Celly Nutrition's CEO.
However, the announcement lacks critical information about the licensing agreement structure between Quantum and Celly Nutrition, making it impossible to quantify the financial impact to Quantum's revenue stream. Puerto Rico's market (population ~3 million) represents a modest opportunity relative to Quantum's overall business potential.
The unbuzzd product itself has scientific validation through a double-blind placebo-controlled study, which strengthens its market positioning as a differentiated functional beverage. The news indicates business development momentum but lacks sufficient financial detail to be considered a material catalyst for Quantum BioPharma's valuation.
Alcohol Detoxification and Anti-Hangover Beverage (Available on amazon.com and unbuzzd.com) to be Distributed by FUSION in Puerto Rico and Caribbean Region
TORONTO, April 03, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), today announced its licensee – Celly Nutrition Corporation (“Celly Nutrition”), the company behind unbuzzd™ – the beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms – is launching unbuzzd in Puerto Rico with distribution partner FUSION Distribution Group, a leading distributor of health-conscious food and beverage offerings across Puerto Rico, the Caribbean, and parts of Central and South America.
Proven effective in accelerating the reduction of blood alcohol levels and scientifically backed by a double-blind placebo-controlled crossover study, unbuzzd is packed in single, convenient “On-the-Go Powder Stick Packs" to serve Puerto Rico consumers and retailers, exclusively available through FUSION.
Based in Puerto Rico, FUSION is adding unbuzzd to its already impressive portfolio that includes CELSIUS Energy Drinks, SHINE Water, Tona Cerveza, Goli, POWER CRUNCH, and Kin Whiskey. FUSION’s robust distribution network in Puerto Rico includes major retailers and food service operations, including Walmart, Walgreens, Costco, Sam’s, Farmacias Caridad, Pueblo Supermarkets, Supermax, and many more.
John Duffy, CEO of Celly Nutrition, stated, "The launch of unbuzzd in Puerto Rico represents a significant milestone for unbuzzd and the latest step towards our goal of making unbuzzd more widely available at retail. We are proud to work with FUSION, as we expand to Puerto Rico and then to markets across the Caribbean.”
Eduardo Santacana, CEO of FUSION Distribution Group, added: "The FUSION team is very excited to launch unbuzzd across the Caribbean, beginning with Puerto Rico. unbuzzd will be available in grocery, pharmacy, and convenience stores, as well as in hotels, bars, country clubs, and restaurants. Our goal is to place unbuzzd within arm’s reach of every consumer in Puerto Rico.”
About Fusion Distribution Group
Fusion Distribution Group is a leading full-service brand incubator and distributor of health-conscious food and beverage offerings in Puerto Rico, the Caribbean Basin and parts of Central and South America. Fusion’s differentiation is the passion and dedication by which the Fusion team launches and manages brands. Fusion’s internal marketing department collaborates with our partners to ensure a smooth and seamless integration of the brand’s personality, identity, positioning, and image into the Puerto Rico and Caribbean markets.
About Celly Nutrition Corporation
Celly Nutrition, a non-trading but fully-reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. unbuzzd has been developed by a world-class research and development team in pharmacology and medicine, with a commitment to innovation and quality. With a proprietary blend of vitamins, minerals, and herbs, unbuzzd helps your body process alcohol faster, quickly restoring mental alertness, and improving cognition so you can drink responsibly. unbuzzd appeals to a broad target audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day.
Scientifically backed by a recently completed double-blind, randomized, placebo-controlled crossover design clinical trial, unbuzzd dramatically accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration, restores mental clarity, and reduces the symptoms of intoxication, impairment, and hangover. The full press release of the clinical trial can be found here.
unbuzzd™ ready-to-mix powder sticks are available in 3-pack, 8-pack and 18-pack formats at amazon.com and unbuzzd.com.
unbuzzd™ is a registered trademark of Celly Nutrition Corp.
Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after drinking alcohol does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE.
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of
Forward-Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such.
Forward-looking information in this press release are based on certain assumptions and expected future events.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8d8ad8bf-119b-48ec-bba7-f13317a00fd9
FAQ
What is the distribution deal between Quantum BioPharma (QNTM) and FUSION for unbuzzd?
How is unbuzzd's effectiveness proven for QNTM shareholders?
What retail channels will carry QNTM's unbuzzd in Puerto Rico?
What form does QNTM's unbuzzd product come in for the Puerto Rico market?
